Safety of bioelectrical impedance analysis in advanced heart failure patients. Issue 10 (31st July 2020)

• Record Type: Journal Article
• Authors: Roehrich, Luise; Suendermann, Simon; Just, Isabell Anna; Knierim, Jan; Mulzer, Johanna; Mueller, Marcus; Eulert‐Grehn, Jaime‐Juergen; Hummel, Manfred; Starck, Christoph; Potapov, Evgenij; Knosalla, Christoph; Falk, Volkmar; Schoenrath, Felix
• Is Part Of: Pacing and clinical electrophysiology. Volume 43:Issue 10(2020)
• Page Start: 1078
• Page End: 1085
• Publication Date: 2020-07-31
• Subjects: advanced heart failure -- bioelectrical impedance analysis -- electromagnetic interference -- implantable cardiac defibrillator -- sarcopenia -- ventricular assist device; Cardiac pacing -- Periodicals; Electrophysiology -- Periodicals; 617.4120645
• DOI: 10.1111/pace.14018
• Languages: English
• ISSNs: 0147-8389

Abstract

Abstract: Background: Cardiac cachexia and frailty are major complications of advanced heart failure (AHF). Bioelectrical impedance analysis (BIA) may provide valuable information regarding fluid balance, muscle mass and prognosis. The main concerns regarding the use of BIA in AHF patients remain arrhythmias and electromagnetic interferences with cardiac implantable electronic devices (CIEDs). Reliable data regarding patients on continuous‐flow ventricular assist device (cf‐VAD) remain scarce. The aim of this study is to evaluate the safety of BIA in AHF patients on pro‐arrhythmogenic therapy with an implanted CIED and/or with a cf‐VAD. Methods: We prospectively performed 217 BIA measurements in 143 AHF patients at risk of severe arrhythmias due to inotropic support/a history of ventricular arrhythmias and/or treated with CIED, including 104 patients with an ICD, CRT or pacemaker and 95 patients with a cf‐VAD. All patients were under continuous Electrocardiogram (ECG) monitoring and clinical surveillance for 24 hours. Results: No adverse events were observed during the 217 BIA measurements: No rhythm disturbances were documented in the telemetric monitoring during or within 30 minutes after the measurement. CIEDs showed no malfunction, regardless of the location measured or the device manufacturer. In particular, no inappropriate shocks were observed. No alarms, flow disturbances, or malfunctions of the cf‐VAD occurred during or after the measurements. Conclusion: We consider BIA a safe measurement with major clinical relevance in our cohort of AHF patients, despite an increased arrhythmic potential on inotropic support or the presence of implanted electronic devices (ICD, CRT, pacemaker and cf‐VAD).